BioCentury
ARTICLE | Company News

Jazz, MD Anderson partner to evaluate hematologic cancer therapies

August 10, 2018 6:51 PM UTC

University of Texas MD Anderson Cancer Center (Houston, Texas) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to evaluate treatment options for hematologic malignancies, with an initial focus on evaluating and generating additional data for Vyxeos daunorubicin/cytarabine.

The five-year deal will explore Vyxeos in new patient populations and in combination with other therapies. The drug is approved in the U.S. to treat acute myelogenous leukemia (AML)...